|
WF10
 The Corporation's WF10 technology's proposed mode of activity is based on a theory about how the macrophage regulates the immune system. Research suggests the drug may correct improperly functioning immune systems. The drug has potential applications in adjuvant cancer therapy, immunology, and the management of chronic viral infections.
WF10 is a chlorite-based, immunomodulating drug. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda® (capecitabine) in the treatment of pancreatic cancer. The trial is being
conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
|
